FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892933731> ?p ?o ?g. }

• W2892933731 endingPage "416" @default.
• W2892933731 startingPage "403" @default.
• W2892933731 abstract "High titers of HLA antibodies are associated with platelet refractoriness, causing poor platelet increments after transfusions in a subset of patients with HLA antibodies. Currently, we do not know the biological mechanisms that explain the variability in clinical responses in HLA alloimmunized patients receiving platelet transfusions. Previously we showed that a subset of anti-HLA IgG-antibodies induces FcγRIIa-dependent platelet activation and enhanced phagocytosis. Here, we investigated whether anti-HLA IgG can induce complement activation on platelets. We found that a subset of anti-HLA IgG induced complement activation via the classical pathway, causing C4b and C3b deposition and formation of the membrane-attack complex. This resulted in permeabilization of platelet membranes and increased calcium influx. Complement activation also caused enhanced α-granule release, as measured by CD62P surface exposure. Blocking studies revealed that platelet activation was caused by FcγRIIa-dependent signaling as well as HLA antibody induced complement activation. Synergistic complement activation employing combinations of monoclonal IgGs suggested that assembly of oligomeric IgG complexes strongly promoted complement activation through binding of IgGs to different antigenic determinants on HLA. In agreement with this, we observed that preventing anti-HLA-IgG hexamer formation using an IgG-Fc:Fc blocking peptide, completely inhibited C3b and C4b deposition. Our results show that HLA antibodies can induce complement activation on platelets including membrane attack complex formation, pore formation and calcium influx. We propose that these events can contribute to fast platelet clearance in vivo in patients refractory to platelet transfusions with HLA alloantibodies, who may benefit from functional-platelet matching and treatment with complement inhibitors." @default.
• W2892933731 created "2018-10-05" @default.
• W2892933731 creator A5001994531 @default.
• W2892933731 creator A5002870795 @default.
• W2892933731 creator A5017033909 @default.
• W2892933731 creator A5021544227 @default.
• W2892933731 creator A5025798456 @default.
• W2892933731 creator A5030808557 @default.
• W2892933731 creator A5048319418 @default.
• W2892933731 creator A5048355604 @default.
• W2892933731 creator A5049460850 @default.
• W2892933731 creator A5054617110 @default.
• W2892933731 creator A5072522782 @default.
• W2892933731 creator A5074307769 @default.
• W2892933731 creator A5079300413 @default.
• W2892933731 creator A5085380635 @default.
• W2892933731 creator A5086507996 @default.
• W2892933731 date "2018-09-27" @default.
• W2892933731 modified "2023-10-12" @default.
• W2892933731 title "Anti-HLA antibodies with complementary and synergistic interaction geometries promote classical complement activation on platelets" @default.
• W2892933731 cites W1503742614 @default.
• W2892933731 cites W1534428859 @default.
• W2892933731 cites W1549415843 @default.
• W2892933731 cites W1577103371 @default.
• W2892933731 cites W1841274444 @default.
• W2892933731 cites W1877141518 @default.
• W2892933731 cites W1904477962 @default.
• W2892933731 cites W1906606630 @default.
• W2892933731 cites W1938219856 @default.
• W2892933731 cites W1972414638 @default.
• W2892933731 cites W1985960971 @default.
• W2892933731 cites W1992665403 @default.
• W2892933731 cites W2001333029 @default.
• W2892933731 cites W2005820202 @default.
• W2892933731 cites W2006084243 @default.
• W2892933731 cites W2013362643 @default.
• W2892933731 cites W2034170740 @default.
• W2892933731 cites W2035960879 @default.
• W2892933731 cites W2039928024 @default.
• W2892933731 cites W2087450488 @default.
• W2892933731 cites W2101578079 @default.
• W2892933731 cites W2117066664 @default.
• W2892933731 cites W2123312213 @default.
• W2892933731 cites W2129106015 @default.
• W2892933731 cites W2138370786 @default.
• W2892933731 cites W2156895814 @default.
• W2892933731 cites W2169656611 @default.
• W2892933731 cites W2252378111 @default.
• W2892933731 cites W2404324152 @default.
• W2892933731 cites W2425420867 @default.
• W2892933731 cites W2556080091 @default.
• W2892933731 cites W2605638326 @default.
• W2892933731 cites W2616639792 @default.
• W2892933731 cites W2733634926 @default.
• W2892933731 cites W2780546185 @default.
• W2892933731 cites W2785721281 @default.
• W2892933731 cites W2793747814 @default.
• W2892933731 cites W2807070453 @default.
• W2892933731 cites W4250903776 @default.
• W2892933731 cites W81741380 @default.
• W2892933731 doi "https://doi.org/10.3324/haematol.2018.201665" @default.
• W2892933731 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6355480" @default.
• W2892933731 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30262558" @default.
• W2892933731 hasPublicationYear "2018" @default.
• W2892933731 type Work @default.
• W2892933731 sameAs 2892933731 @default.
• W2892933731 citedByCount "20" @default.
• W2892933731 countsByYear W28929337312019 @default.
• W2892933731 countsByYear W28929337312020 @default.
• W2892933731 countsByYear W28929337312021 @default.
• W2892933731 countsByYear W28929337312022 @default.
• W2892933731 countsByYear W28929337312023 @default.
• W2892933731 crossrefType "journal-article" @default.
• W2892933731 hasAuthorship W2892933731A5001994531 @default.
• W2892933731 hasAuthorship W2892933731A5002870795 @default.
• W2892933731 hasAuthorship W2892933731A5017033909 @default.
• W2892933731 hasAuthorship W2892933731A5021544227 @default.
• W2892933731 hasAuthorship W2892933731A5025798456 @default.
• W2892933731 hasAuthorship W2892933731A5030808557 @default.
• W2892933731 hasAuthorship W2892933731A5048319418 @default.
• W2892933731 hasAuthorship W2892933731A5048355604 @default.
• W2892933731 hasAuthorship W2892933731A5049460850 @default.
• W2892933731 hasAuthorship W2892933731A5054617110 @default.
• W2892933731 hasAuthorship W2892933731A5072522782 @default.
• W2892933731 hasAuthorship W2892933731A5074307769 @default.
• W2892933731 hasAuthorship W2892933731A5079300413 @default.
• W2892933731 hasAuthorship W2892933731A5085380635 @default.
• W2892933731 hasAuthorship W2892933731A5086507996 @default.
• W2892933731 hasBestOaLocation W28929337311 @default.
• W2892933731 hasConcept C111684460 @default.
• W2892933731 hasConcept C159654299 @default.
• W2892933731 hasConcept C171279029 @default.
• W2892933731 hasConcept C185592680 @default.
• W2892933731 hasConcept C203014093 @default.
• W2892933731 hasConcept C3018697912 @default.
• W2892933731 hasConcept C79196540 @default.
• W2892933731 hasConcept C86803240 @default.
• W2892933731 hasConcept C89560881 @default.

• next